Literature DB >> 10740142

Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension.

A A Lopes1, N Y Maeda, R C Gonçalves, S P Bydlowski.   

Abstract

BACKGROUND: Plasma von Willebrand factor antigen (vWF:Ag) has been used as a marker of endothelial perturbation in a number of vascular disorders. In this study, vWF:Ag was determined as an attempt to evaluate the severity of endothelial cell dysfunction in primary pulmonary hypertension (PPH) and congenital heart disease-associated pulmonary hypertension (CHD-PH) comparatively and to determine its impact on short-term survival. METHODS AND
RESULTS: Clinical, hemodynamic, and biochemical data were obtained from 11 patients with PPH and 24 with CHD-PH. Patient groups were similar in terms of age and pulmonary artery pressure. vWF:Ag was measured by electroimmunodiffusion. Patients were followed up for 1 year and at that time, data collected at the beginning of the study were subjected to univariate and multivariate analyses. vWF:Ag was increased in patients (normal reference value 87% +/- 23% activity, mean +/- SD), with higher levels in the PPH group (231% +/- 89%) in comparison with the CHD-PH group (127% +/- 68%) (P <.001). Multivariate analysis showed that survival was influenced by the underlying cause of pulmonary hypertension and vWF:Ag levels but not by patient age, sex, or pulmonary artery pressure. Seven of 10 nonsurvivors but only 4 of 25 survivors had PPH (P =.007). vWF:Ag was 255% +/- 90% in the nonsurvivor group and 121% +/- 54% in the survivors (P <.001).
CONCLUSIONS: Our findings suggest that short-term survival is related to the severity of endothelial cell dysfunction in pulmonary hypertension. In addition, exceedingly high vWF:Ag levels in PPH might reflect a particular pattern of endothelial cell dysfunction that could be associated with decreased short-term life expectancy in this disorder compared with secondary forms of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10740142     DOI: 10.1016/s0002-8703(00)90038-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  10 in total

Review 1.  How valid are animal models to evaluate treatments for pulmonary hypertension?

Authors:  Maria E Campian; Maxim Hardziyenka; Martin C Michel; Hanno L Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09       Impact factor: 3.000

Review 2.  Congenital heart disease and pulmonary arterial hypertension in South America (2013 Grover Conference series).

Authors:  Antonio Augusto Lopes; Patricia C Flores; Gabriel F Diaz; Sonia M F Mesquita
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

3.  Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.

Authors:  Nilesh Gupta; Jahidur Rashid; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2017-02-17       Impact factor: 4.939

4.  Senescent endothelial progenitor cells from dogs with pulmonary arterial hypertension: a before-after self-controlled study.

Authors:  Liang Xia; Jun-hui Zhu; Fu-yu Qiu; Ying Yang; Xu-dong Xie; Xing-xiang Wang; Jun-zhu Chen; Guo-sheng Fu
Journal:  J Physiol Sci       Date:  2009-07-28       Impact factor: 2.781

5.  Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Zeenat Safdar; Emilio Tamez; Adaani Frost; Danielle Guffey; Charles G Minard; Mark L Entman
Journal:  Int J Cardiovasc Res       Date:  2015

6.  Platelets in pulmonary vascular physiology and pathology.

Authors:  Michael H Kroll; Vahid Afshar-Kharghan
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

7.  Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.

Authors:  Djuro Kosanovic; Baktybek Kojonazarov; Himal Luitel; Bhola K Dahal; Akylbek Sydykov; Teodora Cornitescu; Wiebke Janssen; Ralf P Brandes; Neil Davie; Hossein A Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Ralph T Schermuly
Journal:  Respir Res       Date:  2011-06-23

8.  Factors influencing outcomes in patients with Eisenmenger syndrome: a nine-year follow-up study.

Authors:  Mariana M Clavé; Nair Y Maeda; Claudia R P Castro; Sergio P Bydlowski; Antonio A Lopes
Journal:  Pulm Circ       Date:  2017-08-25       Impact factor: 3.017

Review 9.  A narrative review of research advances in hypoxic pulmonary hypertension.

Authors:  Tianci Chai; Chen Qiu; Zhihong Xian; Yongzhen Lu; Yuwei Zeng; Jie Li
Journal:  Ann Transl Med       Date:  2022-02

Review 10.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.